Advertisement

Topics

Latest "Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia" News Stories

11:14 EDT 19th March 2019 | BioPortfolio

Here are the most relevant search results for "Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia" found in our extensive news archives from over 250 global news sources.

More Information about Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia for you to read. Along with our medical data and news we also list Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia Clinical Trials, which are updated daily. BioPortfolio also has a large database of Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia Companies for you to search.

Showing "Combination Chemotherapy With Without Peripheral Stem Cell Transplantation" News Articles 1–25 of 11,000+

Tuesday 19th March 2019

Multiple Myeloma-Causing Plasma Cells Show Intense Uptake of Intravenous Liposomal Curcumin as Reported by SignPath Pharma, Inc. in Paper Published in the Cancer Research Journal “Anticancer Research”

SignPath Pharma, Inc. reported in the March issue of Anticancer Research* that its proprietary intravenous liposomal curcumin (LipoCurc™) concentrates very intensely in the malignant plasma cells that cause


Rex Medical Completes Patient Enrollment for the REVEAL Peripheral Atherectomy U.S. Trial

Rex Medical, L.P., a medical device design and development company, today announced the successful completion of enrollment in the Revolution™ Peripheral Atherectomy System for Lower Extremity Peripheral Arterial Revascularization (REVEAL) IDE clinical trial. The REVEAL trial is a single arm, prospective study to evaluate the safety and effectiven...

FDA approves atezolizumab for extensive-stage small cell lung cancer

The Food and Drug Administration (FDA) approved atezolizumab in combination with carboplatin and etoposide, for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). Approval was based on IMpower133...


VisionCare, Inc. Announces Regulatory Approval of the CentraSight Treatment Program in Australia

The Telescope Implant for End-Stage Macular Degeneration is Approved and Available Around the World in Patients Who Meet Age Requirements and Who Have Not Had Cataract Surgery VisionCare, Inc. ("VisionCare”), a developer of advanced visual prosthetic devices for the treatment of age-related macular degeneration (AMD), today announced that the Au...

Israel’s @SHEBA_ to Manufacture Cell Therapies Using @LonzaGroup’s Cocoon Platform: http://ow.ly/Hyaw30o6z3h pic.twitter.com/QDmtQKsGSu

Israel’s @SHEBA_ to Manufacture Cell Therapies Using @LonzaGroup’s Cocoon Platform: http://ow.ly/Hyaw30o6z3h  pic.twitter.com/QDmtQKsGSu

Arix Bioscience acquires stake in novel firm developing sickle cell treatment

Arix Bioscience PLC (LON:ARIX) investment director John Cassidy talks Proactive London through its decision to invest US$15mln (£11.3mln) in Imara - a firm which is developing treatments for sickle cell disease. Through the deal Arix receives a 10% stake in the company while also expanding the breadth of its portfolio.

Israel’s Sheba Medical Center to Manufacture Cell Therapies Using Lonza’s Cocoon Platform

Lonza said its CocoonTM manufacturing platform will be used by Israel’s largest hospital, Sheba Medical Center at Tel Hashomer, to develop point-of-care cell-therapy manufacturing, through a collaboration whose value was not disclosed. Sheba specializes in treating oncology patients using chimeric antigen receptor T-cell (CAR-T) and other novel immunotherapies. The partnership will enable Sheba...

Sheba Medical Center to Collaborate with Lonza Pharma on State-of-the-Art "Cocoon" Platform to Aid Cancer Patients' Access to Life-Saving CAR-T Immunotherapy Treatments

Israel’s Sheba Medical Center, Tel HaShomer and Swiss-based Lonza Pharma begin collaboration to assess automated CAR-T cell therapy manufacturing at the point-of care. The joint-effort is a move that seeks to leverage expertise in oncology to save lives and lower costs for patients. RAMAT GAN, Israel and BASEL, Switzerland (PRWEB) March 19, 2019 Sheba Medical Center at Tel HaShomer, the largest...

Limitations in Single-Cell Analysis Must Be Addressed with Innovation -- http://ow.ly/K9Cn30o6vSW pic.twitter.com/Oq83hVQjWT

Limitations in Single-Cell Analysis Must Be Addressed with Innovation -- http://ow.ly/K9Cn30o6vSW  pic.twitter.com/Oq83hVQjWT

Mentice and RAD-AID Collaborate to Help Improve Access to Interventional Radiology in Resource-Constrained Regions of the World

Mentice AB, the world-leading provider of endovascular performance solutions, has signed an agreement with the nonprofit public service RAD-AID to donate high-fidelity simulators for Interventional Radiology (IR) procedure training in various resource-constrained regions of the world. Under the agreement, Mentice pledges to contribute simulator softwa...

VetStem Biopharma is Pleased to Share the Success Story of Bogey Who Was Treated with VetStem Cell Therapy by Dr. Ava DeCozio

Bogey, a Labrador retriever, had both cruciate ligaments and an arthritic hip treated with VetStem Regenerative Cell Therapy by Dr. Ava DeCozio of VCA Apache Junction Animal Hospital. POWAY, Calif. (PRWEB) March 19, 2019 Bogey was nine years old when he injured both of his cruciate ligaments. On top of that, Bogey has advanced arthritis in his left hip. These ailments caused Bogey to experience...

Advances in Biologics Development to be Discussed at Symposium Hosted by the Catalent Applied Drug Delivery Institute at the UCSF Mission Bay Campus

The Catalent Applied Drug Delivery Institute today announced that it is to hold a one-day symposium entitled “Advances in Biologics Development and Delivery” on Thursday, March 28, 2019 at the University of California, San Francisco (UCSF), Mission Bay Campus, San Francisco. SOMERSET, N.J. (PRWEB) March 19, 2019 The Catalent Applied Drug Delivery Institute today announced that it is to hold a...

Roche's Tecentriq gains new US lung cancer indication

Roche’s Tecentriq (atezolizumab) cancer immunotherapy has gained a new indication in the US, after the FDA granted it a licence in a difficult to treat form of lung cancer in combination with chemotherapy. The regulator granted the new indication ...

Omeros Corporation Announces Upcoming Educational Event at the Annual Meeting of the European Society of Blood and Marrow Transplantation

--Session Will Focus on Diagnosis of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy-- Omeros Corporation (Nasdaq: OMER) today announced an upcoming educational event at the 2019 Annual Meeting of the European Society of Blood and Marrow Transplantation to be held in Frankfurt, Germany on March 24-27, 2019. Sponsored by Om...

Limitations in Single-Cell Analysis Must Be Addressed with Innovation

Single-cell analysis is transforming how we understand disease, with a growing recognition that cell populations harbor far more heterogeneity than expected—and that bulk population analysis is inadequate for fully characterizing biological complexity. Advances in single-cell genomics, transcriptomics, and proteomics will enable significant improvements in how we approach the clinical research, ...

Nature Publishing Group Study Highlights Potential of Indee Labs Technology as an Alternative to Current Gene-Modified Cell Therapy Manufacturing

Microfluidic method could speed up life-saving chimeric antigen receptor T cell (CAR-T) treatments for advanced cancer patients and solve the scalability challenges Indee Labs announced the publication of a proof-of-concept study demonstrating the efficacy of its gene-modified cell therapy (GMCT) development and manufacturing technology in Nature’s

Pulse Biosciences Appoints Mitchell Levinson to Board of Directors

Pulse Biosciences, Inc.(NASDAQ:PLSE) (“Pulse Biosciences” or the “Company”), a novel medical therapy company bringing to market its proprietary CellFX™ System, today announced the appointment of Mitchell Levinson to its board of directors. In connection with his appointment to the board, Mr. Levinson will also serve as a member of the audit commi...

Clovis Oncology Announces Presentations at 2019 AACR Annual Meeting

Accepted abstracts highlight data from a phase 2 investigator-initiated trial of Rubraca® (rucaparib) in pancreatic cancer, clinical and nonclinical research of Rubraca in multiple solid tumor settings, and nonclinical research exploring lucitanib in multiple solid tumor models Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that six abstracts ...

Standardized Classification, Reporting of Glomerulonephritis

A more standardized approach to the classification and reporting of glomerulonephritis will help nephrologists better evaluate, treat, and manage these patients. Nephrology Dialysis Transplantation

Waters Addresses Increasing Demands for Higher Performing Materials with New TA Innovations at Pittcon

Additionally, Waters Spotlights Biopharmaceutical Solutions with Pittcon Debut of the BioAccord System Waters Corporation (NYSE:WAT) today announced the availability of a range of new TA Instruments™ innovations headlined by the Discovery™ Thermomechanical Analyzer (TMA) 450, a

Magenta Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Business Highlights

-- Declared development candidate in first targeted conditioning program -- -- Phase 1 study for first-line stem cell mobilization program to begin 1H19 -- -- Presented updated clinical data for MGTA-456 cell therapy showing signs of early benefit in patients with inherited metabolic disorders (IMDs) -- -- Ended 201...

DogsLife Offers Financial Assistance for Canine Cancer Treatments in North Texas

Local non-profit teams up with VCA Animal Diagnostic Clinic oncologists to provide hope and help with Sir Desmond’s cancer care A new non-profit organization, DogsLife, is offering pet parents financial aid so they can obtain state-of-the-art cancer treatment by any board-certified veterinary oncologist in North Texas. The latest beneficiary of oncol...

Merck To Collaborate with GenScript to Accelerate Cell and Gene Therapy Industrialization in China

- Collaboration to build global-standard platform for plasmid and virus manufacturing in China - Merck plans to provide comprehensive products, services and training to GenScript on manufacturing ...

Cell Mogrify gets £420k funding for regenerative cell therapies

UK cell therapy company Cell Mogrify has been awarded £420,000 funding from Innovate UK to accelerate its data-driven cell conversion programmes. The funding from the UK’s innovation agency will be used to transition three products to preclinical ...

Roche gets FDA nod for Tecentriq in small cell lung cancer

Ending a 20-year drought in new therapies for patients


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks